Our portfolio of in-house precision oncology solutions delivers rapid, reliable CGP insights in laboratories worldwide and is backed by advanced proprietary bioinformatics
Personal Genome Diagnostics (PGDx) creates clarity for patients with cancer and their clinicians by removing barriers to precision oncology testing in order to make timely, personalized cancer treatments a reality for all.
We unlock a deeper understanding of tumor biology to drive biomarker-informed treatment plans by enabling in-house tumor profiling with our portfolio of RUO and IVD tissue, liquid biopsy-based genomic products, and robust bioinformatics because all patients deserve a chance to lead their best lives.
Today, 80% of patients aren’t being tested, or aren’t being tested in the window of time that it actually makes a difference for their treatment decisions. We are changing that.
The work we’re doing at PGDx is enabling better research, better diagnostics, and better therapy for patients with cancer. I can think of nothing more worthy to spend time and money on.
Kenneth C. Valkenburg, PhD, Senior Manager, Product Development
Whether providing real-time therapy, guiding results to current patients, or through collaborations in biomarker discovery and diagnostic design, our efforts will ultimately shape outcomes for future patients with cancer worldwide. What an incredible honorable opportunity to be a part of!
Amy Greer, PhD, MB (ASCP), Director, CLIA Operations
PGDx gave meaning to my practical career choice. I am extremely fortunate to be able to support an organization and group of individuals with a mission, whose ultimate goal is to help millions of people get through the hardest part of their or their loved one’s lives.
Ana Bacchus, CPA, Controller
I am inspired to work at PGDx because we are at the forefront of a change in cancer patient care. Bringing this technology to patients all over the world is a noble goal, and I am glad to be a part of it.
Andrew Georgiadis, Senior Scientist
When a sample comes into the CLIA lab, I think of the patient behind that sample. I think of someone likely in the most difficult fight of their life seeking answers and hope towards this terrible disease.
Erika (Brooks) Likoudis, MB (ASCP), Associate Validation Scientist